12 November 2019 - Collaborative project with NICE and CADTH leads to important adaptations for ICER’s methods including creation of optimistic and conservative benefit scenarios; new dimensions of benefits and contextual considerations for voting; and two new scenarios that display the potential impact on pricing that would result from sharing the savings of downstream cost offsets between society and the manufacturer.

The Institute for Clinical and Economic Review (ICER) has finalised a set of adaptations to its value assessment framework to be applied when assessing potential cures and other treatments that qualify as high-impact “single or short-term therapies,” or SSTs. These new methods have emerged from a year-long collaborative project with the National Institute for Health and Care Excellence (NICE) in the UK and the Canadian Agency for Drugs and Technologies in Health (CADTH), and they have evolved from preliminary proposals with ongoing input from multiple stakeholder groups. 

It is important to note that these methods adaptations will be implemented by ICER and do not represent preliminary judgments on methodology by either NICE or CADTH. The newly adapted methods will be launched by ICER with reviews commencing in 2020 as part of ICER’s overall update to our value assessment framework.

Read ICER Announcement